<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817541</url>
  </required_header>
  <id_info>
    <org_study_id>Expiratory propofol gastro</org_study_id>
    <nct_id>NCT03817541</nct_id>
  </id_info>
  <brief_title>Expiratory and Plasma Propofol Concentration in Gastrological Surgery Patients</brief_title>
  <official_title>Expiratory and Plasma Propofol Concentration in Bariatric and Cholecystectomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of accuracy With Edmond (reg) expiratory propofol measurement Device, compared
      With concommitant plasma samples of propofol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Edmon (trade mark) is a New Device from BBraun, measuring the expiratory concentration of
      propofol in anaesthetized patients.

      The investigators will test the accuracy and stability of such measurements in comparison
      With plasma propofol Levels.

      The investigators will test during target Control infusion (Marsh model) and assumed stable
      plasma Levels.

      Plasma samples of propofol will be taken for comparison With exhaled propofol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One Group of morbidly obese patients for bariatric surgery One Group of normal weight cholecystectomy</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exhaled propofol concentration</measure>
    <time_frame>start of anaesthesia to end of anaesthesia, 2-3 hours in total</time_frame>
    <description>parts per billion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>propofol plasma concentration</measure>
    <time_frame>4-6 samples in the period between start and end of anaesthesia</time_frame>
    <description>microg pr ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>calculated plasma concentration</measure>
    <time_frame>From start of anaesthesia until end of anaesthesia, 1-3 hrs in total</time_frame>
    <description>Marsh model prediction, microg pr ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS</measure>
    <time_frame>from start of anaesthesia until end of anaestheisa, 1-3 hours in total</time_frame>
    <description>Bispectral index value, score = 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calculated effect site concentration</measure>
    <time_frame>from start of anaesthesia until end of anaesthesia, 1-3 hours in total</time_frame>
    <description>Marsh model, microg pr ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG Power spectrum</measure>
    <time_frame>f</time_frame>
    <description>Spectral edge value (Hz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG Power distribution</measure>
    <time_frame>from start of anaesthesia until end of anaesthesia, 1-3 hours in total</time_frame>
    <description>% representation relative Power of Alpha, Beta, Theta, Gamma band</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>Bariatric surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients due for bariatric surgery, BMI &gt; 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecystectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal weight patients due for cholecystectomies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edmon (reg), BBraun</intervention_name>
    <description>exhaled propofol will be compared With plasma propofol values</description>
    <arm_group_label>Bariatric surgery</arm_group_label>
    <arm_group_label>Cholecystectomy</arm_group_label>
    <other_name>propofol plasma sample</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Patients admitted to Oslo University Hospital, scheduled for elective laparoscopic
             bariatric surgery or elective laparoscopic cholecystectomy.

               -  Both genders.

               -  Age 18-60 years, both inclusive.

               -  BMI ≥ 20 kg/m2, 10 patients with BMI 20-30, and 10 patients with BMI &gt; 40

               -  ASA classification I-III

        Exclusion Criteria:

          -  • Known hypersensitivity or other contraindication to propofol administered as Target
             Controlled Infusion.

               -  Patients which during a preoperative visit are deemed not to tolerate propofol
                  bolus or infusion as administered by Target Controlled Infusion.

               -  Ongoing neuroleptic medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Anesthesiology, Oslo University Hospital, Ullevaal</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Raeder</last_name>
      <phone>+47 92249669</phone>
      <email>johan.rader@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Johan Raeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>February 2, 2019</last_update_submitted>
  <last_update_submitted_qc>February 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Johan C Ræder</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

